General Information of Drug (ID: DMZ5RGV)

Drug Name
Naproxen Drug Info
Synonyms
NAPROXEN; 22204-53-1; (S)-Naproxen; Naproxene; Naprosyn; (+)-Naproxen; Equiproxen; Laraflex; Naproxenum; Naproxeno; d-Naproxen; (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid; (S)-(+)-Naproxen; Calosen; Nycopren; Naprosyne; Bonyl; Reuxen; Naixan; Axer; (+)-(S)-Naproxen; Ec-Naprosyn; (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid; Flexipen; Clinosyn; Artrixen; Anexopen; Acusprain; Novonaprox; Arthrisil; Leniartil; Danaprox; Bipronyl; Artroxen; Napren; Naposin; Napflam; Genoxen; Daprox; Atiflan; Artagen; Apronax; Naprius; Nalyxan; Lefaine; Congex
Indication
Disease Entry ICD 11 Status REF
Bursitis Approved [1]
Dysmenorrhea GA34.3 Approved [1]
Fever MG26 Approved [1]
Gout FA25 Approved [1]
Headache 8A80-8A84 Approved [1]
Migraine disorder Approved [1]
Osteoarthritis FA00-FA05 Approved [2]
Pain MG30-MG3Z Phase 2 [3]
Endometriosis GA10 Investigative [4]
Cross-matching ID
PubChem CID
156391
ChEBI ID
CHEBI:7476
CAS Number
CAS 22204-53-1
TTD Drug ID
DMZ5RGV
VARIDT Drug ID
DR00603
INTEDE Drug ID
DR1130
ACDINA Drug ID
D00456

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DME
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [18]
Mesalazine DMOL5IU Diverticulitis Approved [19]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [20]
Bromfenac DMKB79O Pain MG30-MG3Z Approved [21]
Aminosalicylic Acid DMENSL5 Crohn disease DD70 Approved [22]
Flufenamic Acid DMC8VNH Dysmenorrhea GA34.3 Approved [23]
Piroxicam DMTK234 Osteoarthritis FA00-FA05 Approved [22]
Suprofen DMKXJZ7 Miosis LA11.62 Approved [24]
Gamma-Homolinolenic acid DMSXKYG Malnutrition 5B50-5B71 Approved [25]
FENBUFEN DMXGDFK Arthritis FA20 Approved [26]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [27]
Etodolac DM6WJO9 Osteoarthritis FA00-FA05 Approved [28]
Indomethacin DMSC4A7 Bursitis Approved [22]
Celecoxib DM6LOQU Dysmenorrhea GA34.3 Approved [29]
Nabumetone DMAT2XH Osteoarthritis FA00-FA05 Approved [30]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [31]
Flurbiprofen DMGN4BY Osteoarthritis FA00-FA05 Approved [32]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [20]
Aminosalicylic Acid DMENSL5 Crohn disease DD70 Approved [22]
Lumiracoxib DM1S4AG Chronic renal failure GB61.Z Approved [33]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [34]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [35]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [36]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [37]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [38]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [39]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [40]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [41]
Verapamil DMA7PEW Angina pectoris BA40 Approved [42]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [43]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [44]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [45]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [46]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [47]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [48]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [49]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [50]
Metronidazole DMTIVEN Abscess Approved [51]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [52]
Ethanol DMDRQZU Chronic pain MG30 Approved [53]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2C8 (CYP2C8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [34]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [54]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [54]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [55]
Verapamil DMA7PEW Angina pectoris BA40 Approved [56]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [57]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [58]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [54]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [59]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [60]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2C9 (CYP2C9)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [61]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [62]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [63]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [55]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [64]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [55]
Verapamil DMA7PEW Angina pectoris BA40 Approved [65]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [66]
Estrone DM5T6US Acne vulgaris ED80 Approved [67]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [68]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [97]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [98]
Dapsone DM4LT8A Acne vulgaris ED80 Approved [99]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [100]
Capsaicin DMGMF6V Back pain ME84.Z Approved [101]
Zafirlukast DMHNQOG Asthma CA23 Approved [102]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [99]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [103]
Fluconazole DMOWZ6B Cryptococcal meningitis Approved [100]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [99]
⏷ Show the Full List of 20 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [69]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [70]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [9]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [71]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [59]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [9]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [72]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [73]
Ezetimibe DM7A8TW Atherosclerosis BD40 Approved [74]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [75]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [76]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [49]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [9]
Atorvastatin DMF28YC Acute coronary syndrome BA41 Approved [77]
Cerivastatin DMXCM7H Hyperlipidaemia 5C80 Approved [78]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [72]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [73]
Ezetimibe DM7A8TW Atherosclerosis BD40 Approved [79]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [75]
Losartan DM72JXH Diabetic kidney disease GB61.Z Approved [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [80]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [76]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [81]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [9]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [82]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [9]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [9]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [83]
Nateglinide DMLK2QH Diabetic complication 5A2Y Approved [9]
Haloperidol DM96SE0 Delirium Approved [9]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [84]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [85]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [50]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [86]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [73]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [87]
Deferiprone DMS2M7O Beta thalassemia 3A50.2 Approved [88]
ANDROSTERONE DMITJAK N. A. N. A. Phase 3 [89]
BCP-13498 DM2BO9W N. A. N. A. Phase 2 [90]
LM-94 DMW3QGJ N. A. N. A. Phase 1/2 [91]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [92]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [85]
Mycophenolate mofetil DMPQAGE Hepatosplenic T-cell lymphoma Approved [93]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [73]
Losartan DM72JXH Diabetic kidney disease GB61.Z Approved [9]
Etodolac DM6WJO9 Osteoarthritis FA00-FA05 Approved [9]
Raloxifene DMDKF3M Osteoporosis FB83.0 Approved [94]
Bazedoxifene DMY85QW Hot flushes GA30 Approved [95]
BCP-13498 DM2BO9W N. A. N. A. Phase 2 [96]
⏷ Show the Full List of 9 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [104]
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [105]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [105]
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [106]
Lamivudine DMI347A Chronic HBV infection 1E51.0Z Approved [107]
Famotidine DMRL3AB Gastric ulcer DA60 Approved [106]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [108]
Trospium chloride DM32XZT Discovery agent N.A. Approved [109]
Phenoxybenzamine DM8KSQH Malignant essential hypertension BA00 Approved [110]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [111]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [112]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [108]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [108]
Quercetin DM3NC4M Obesity 5B81 Approved [113]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [108]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [108]
Succinic acid DMDWICP Malnutrition 5B50-5B71 Approved [114]
Mefenamic acid DMK7HFI Dysmenorrhea GA34.3 Approved [108]
Probenecid DMMFWOJ Acute gonococcal cervicitis Approved [115]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [108]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [108]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [108]
Quercetin DM3NC4M Obesity 5B81 Approved [116]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [117]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [118]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [108]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [108]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [119]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [120]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [121]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [108]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [108]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [121]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [108]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [108]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [122]
Mefenamic acid DMK7HFI Dysmenorrhea GA34.3 Approved [108]
Probenecid DMMFWOJ Acute gonococcal cervicitis Approved [123]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [108]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [124]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aspirin DM672AH Acute coronary syndrome BA41 Approved [108]
Methotrexate DM2TEOL Anterior urethra cancer Approved [125]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [117]
Paclitaxel DMLB81S Breast carcinoma Approved [126]
Allopurinol DMLPAOB Gout FA25 Approved [126]
Bumetanide DMRV7H0 Congestive heart failure BD10 Approved [126]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [126]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [126]
Tetracycline DMZA017 Acne vulgaris ED80 Approved [126]
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [106]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [127]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [128]
Flupentixol DM0DJ9O Schizophrenia 6A20 Approved [129]
Quercetin DM3NC4M Obesity 5B81 Approved [130]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [131]
Penicillamine DM40EF6 Cystinuria 5C60.2 Approved [132]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [133]
Bupivacaine DM4PRFC Anaesthesia 9A78.6 Approved [134]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [133]
Panobinostat DM58WKG Chronic graft versus host disease Approved [135]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [136]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [137]
Gamolenic acid DMQN30Z Allergy 4A80-4A85 Approved [138]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [139]
Flupentixol DM0DJ9O Schizophrenia 6A20 Approved [129]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [140]
Ibandronate DM0QZBN Hypercalcaemia 5B91.0 Approved [141]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [142]
Fexofenadine DM17ONX Allergic rhinitis CA08.0 Approved [143]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [144]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [145]
Trametinib DM2JGQ3 Melanoma 2C30 Approved [146]
Methotrexate DM2TEOL Anterior urethra cancer Approved [125]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [147]
Panobinostat DM58WKG Chronic graft versus host disease Approved [135]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [148]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [148]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [149]
Oxaprozin DM9UB0P Osteoarthritis FA00-FA05 Approved [150]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [119]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [151]
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [12]
Diazepam DM08E9O Alcohol withdrawal Approved [152]
Levonorgestrel DM1DP7T Atypical endometrial hyperplasia Approved [153]
Desogestrel DM27U4Y Contraception QA21 Approved [153]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [12]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [12]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [154]
Quercetin DM3NC4M Obesity 5B81 Approved [155]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [156]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [12]
Diazepam DM08E9O Alcohol withdrawal Approved [152]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [157]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [158]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [12]
Quercetin DM3NC4M Obesity 5B81 Approved [116]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [159]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [12]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [160]
Testosterone DM7HUNW Hot flushes GA30 Approved [161]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [162]
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [12]
Diazepam DM08E9O Alcohol withdrawal Approved [152]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [163]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [12]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [12]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [164]
Glimepiride DM5FSJA Diabetic complication 5A2Y Approved [165]
Ethacrynic acid DM60QMR Edema MG29 Approved [163]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Bile salt export pump (ABCB11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glimepiride DM5FSJA Diabetic complication 5A2Y Approved [166]
Ezetimibe DM7A8TW Atherosclerosis BD40 Approved [15]
Glipizide DMZA5PQ Diabetic complication 5A2Y Approved [15]
Bosentan DMIOGBU Pulmonary arterial hypertension BB01.0 Approved [167]
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [166]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [15]
Primidone DM0WX6I Epilepsy 8A60-8A68 Approved [168]
Gefitinib DM15F0X Colon adenocarcinoma Approved [166]
Drospirenone DM1A9W3 Acne vulgaris ED80 Approved [169]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [166]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tolbutamide DM02AWV Advanced cancer 2A00-2F9Z Approved [13]
Diazepam DM08E9O Alcohol withdrawal Approved [13]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [170]
Selenium DM25CGV N. A. N. A. Approved [171]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [13]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [13]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [13]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [13]
Omeprazole DM471KJ Cystic fibrosis CA25 Approved [13]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Renin (REN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [172]
Acebutolol DM0TI4U Hypertension BA00-BA04 Approved [173]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [174]
Reboxetine DM26PRD Depression 6A70-6A7Z Approved [175]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [176]
Ramipril DM2R68E Acute heart failure BD10-BD13 Approved [177]
Rhucin DM3ADGP Erectile dysfunction HA01.1 Approved [178]
Naloxone DM3FXMA Narcotic depression 6A7Z Approved [179]
Epinephrine DM3KJBC Acute asthma CA23 Approved [180]
Chlorthalidone DM4DMBT Edema MG29 Approved [181]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Albumin (ALB)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [182]
Sulfamethoxazole DMB08GE Acute otitis media AB00 Approved [183]
Tolbutamide DM02AWV Advanced cancer 2A00-2F9Z Approved [184]
Diazepam DM08E9O Alcohol withdrawal Approved [185]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [186]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [187]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [188]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [189]
Methotrexate DM2TEOL Anterior urethra cancer Approved [190]
Quercetin DM3NC4M Obesity 5B81 Approved [191]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flupentixol DM0DJ9O Schizophrenia 6A20 Approved [192]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [193]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [194]
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [195]
Cepharanthine DM9Y5JB N. A. N. A. Approved [196]
Itraconazole DMCR1MV Aspergillosis 1F20 Approved [197]
Clozapine DMFC71L Schizophrenia 6A20 Approved [198]
Midostaurin DMI6E0R Acute myeloid leukaemia 2A60 Approved [199]
Trifluoperazine DMKBYWI Anxiety Approved [200]
Olanzapine DMPFN6Y Bipolar depression Approved [198]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Topiramate DM82Z30 Alcohol dependence 6C40.2 Approved [201]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [149]
Valdecoxib DMAY7H4 Osteoarthritis FA00-FA05 Approved [201]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [128]
Ethosuximide DMDZ9LT Epilepsy 8A60-8A68 Approved [201]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [202]
Vancomycin DM3JFIH Bacteremia 1A73 Approved [201]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [203]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [204]
Bortezomib DMNO38U Leukemia Approved [205]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [206]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [207]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [208]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [209]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [210]
Quercetin DM3NC4M Obesity 5B81 Approved [211]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [212]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [213]
Acetic Acid, Glacial DM4SJ5Y infection in the ear canal AA0Y Approved [214]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [215]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [206]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [216]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [209]
Quercetin DM3NC4M Obesity 5B81 Approved [217]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [213]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [218]
Acetic Acid, Glacial DM4SJ5Y infection in the ear canal AA0Y Approved [219]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [220]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [221]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [222]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 4A11 (CYP4A11)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Clofibrate DMPC1J7 Dysbetalipoproteinemia 5C80.2 Approved [223]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [17]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [17]
Methotrexate DM2TEOL Anterior urethra cancer Approved [224]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [225]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [133]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [133]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [17]
Etodolac DM6WJO9 Osteoarthritis FA00-FA05 Approved [17]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [17]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Captopril DM458UM Chronic heart failure BD1Z Approved [226]
Diazepam DM08E9O Alcohol withdrawal Approved [13]
Dantrolene DM1D8XY Hyperthermia MG26 Approved [13]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [13]
Imipramine DM2NUH3 Depression 6A70-6A7Z Approved [13]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [13]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [13]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [13]
Penicillamine DM40EF6 Cystinuria 5C60.2 Approved [13]
Omeprazole DM471KJ Cystic fibrosis CA25 Approved [13]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Testosterone DM7HUNW Hot flushes GA30 Approved [227]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [227]
Gefitinib DM15F0X Colon adenocarcinoma Approved [228]
Sunitinib DMCBJSR Acute undifferentiated leukemia Approved [183]
Rosuvastatin DMMIQ7G Arteriosclerosis BD40 Approved [229]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [230]
Methotrexate DM2TEOL Anterior urethra cancer Approved [231]
Quercetin DM3NC4M Obesity 5B81 Approved [232]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [117]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [233]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 1 (COX-1) TT8NGED PGH1_HUMAN Inhibitor [5]
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9) Main DME DE5IED8 CP2C9_HUMAN Substrate [6]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [7]
Cytochrome P450 1A2 (CYP1A2) Main DME DEJGDUW CP1A2_HUMAN Substrate [8]
Cytochrome P450 2C8 (CYP2C8) Main DME DES5XRU CP2C8_HUMAN Substrate [8]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Substrate [9]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [10]
UDP-glucuronosyltransferase 1A10 (UGT1A10) DEL5N6Y UD110_HUMAN Substrate [10]
UDP-glucuronosyltransferase 1A6 (UGT1A6) DESD26P UD16_HUMAN Substrate [10]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Substrate [10]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Albumin (ALB) OTVMM513 ALBU_HUMAN Protein Interaction/Cellular Processes [11]
Aldo-keto reductase family 1 member C1 (AKR1C1) OTQKR4CM AK1C1_HUMAN Gene/Protein Processing [12]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Gene/Protein Processing [12]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Gene/Protein Processing [12]
Angiotensin-converting enzyme 2 (ACE2) OTTRZGU7 ACE2_HUMAN Gene/Protein Processing [13]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Gene/Protein Processing [14]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [15]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Gene/Protein Processing [14]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Biotransformations [16]
Cytochrome P450 4A11 (CYP4A11) OTPU5J0S CP4AB_HUMAN Gene/Protein Processing [17]

References

1 Naproxen FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5230).
4 New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202.
5 Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
6 Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc. 2004 Mar;135(3):298-311.
7 Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genomics. 2007 Dec;17(12):1017-29.
8 Involvement of multiple cytochrome P450 isoforms in naproxen O-demethylation. Eur J Clin Pharmacol. 1997;52(4):293-8.
9 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
10 S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
11 Biological evaluation of cobalt(II) complexes with non-steroidal anti-inflammatory drug naproxen. J Inorg Biochem. 2012 Feb;107(1):54-64. doi: 10.1016/j.jinorgbio.2011.10.014. Epub 2011 Nov 3.
12 Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
13 Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
14 Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm Res. 2008 Sep;25(9):1991-2001. doi: 10.1007/s11095-008-9596-1. Epub 2008 Jun 26.
15 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
16 Differential activation of CYP2C9 variants by dapsone. Biochem Pharmacol. 2004 May 15;67(10):1831-41.
17 Effects of acidic non-steroidal anti-inflammatory drugs on human cytochrome P450 4A11 activity: Roles of carboxylic acid and a sulfur atom in potent inhibition by sulindac sulfide. Chem Biol Interact. 2023 Sep 1;382:110644. doi: 10.1016/j.cbi.2023.110644. Epub 2023 Jul 25.
18 The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
19 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
20 Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
21 Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
22 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
23 Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
24 Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
25 Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
26 Fenbufen based 3-[5-(substituted aryl)-1,3,4-oxadiazol-2-yl]-1-(biphenyl-4-yl)propan-1-ones as safer antiinflammatory and analgesic agents. Eur J Med Chem. 2009 Sep;44(9):3798-804.
27 Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
28 Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
29 Pfizer. Product Development Pipeline. March 31 2009.
30 Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
31 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
32 Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
33 Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur Respir J. 2009 Jul;34(1):200-8.
34 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
35 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
36 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
37 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
38 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
39 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
40 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
41 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
42 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
43 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
44 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
45 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
46 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
47 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
48 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
49 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
50 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
51 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
52 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
53 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
54 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
55 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
56 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
57 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
58 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
59 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
60 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
61 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
62 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
63 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
64 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
65 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
66 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
67 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
68 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
69 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
70 Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
71 Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
72 Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
73 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
74 Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
75 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
76 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
77 UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
78 Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
79 Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8.
80 Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
81 Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
82 The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
83 The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
84 UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables. Drug Metab Dispos. 2011 Sep;39(9):1650-7.
85 UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6.
86 Pharmacokinetics of propofol and extrahepatic UGT1A6 gene expression in anhepatic rats. Pharmacology. 2009;84(4):219-26.
87 Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria. Allergy Asthma Immunol Res. 2011 Oct;3(4):273-6.
88 Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants. Drug Metab Dispos. 2009 Feb;37(2):322-9.
89 Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev. 1999 Nov;31(4):817-99.
90 Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics. 2004 Aug;14(8):487-99.
91 Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A. J Biol Chem. 2007 Dec 14;282(50):36514-24.
92 Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos. 2007 Nov;35(11):2006-14.
93 [Pharmacology of mycophenolate mofetil: recent data and clinical consequences]. Nephrologie. 2001;22(7):331-7.
94 Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo. Cancer Prev Res (Phila). 2013 Jul;6(7):719-30.
95 In vitro metabolism, permeability, and efflux of bazedoxifene in humans. Drug Metab Dispos. 2010 Sep;38(9):1471-9.
96 UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther. 2005 Apr;106(1):97-132.
97 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
98 Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003 Apr;31(4):439-46.
99 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
100 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
101 Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
102 Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica. 2004 May;34(5):429-38.
103 The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes. Life Sci. 2006 Nov 25;79(26):2432-40.
104 Involvement of aryl hydrocarbon receptor in the cytotoxicity of corannulene and its derivatives. Toxicol Lett. 2020 Mar 15;321:114-121. doi: 10.1016/j.toxlet.2019.12.012. Epub 2019 Dec 9.
105 Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. Food Chem Toxicol. 2012 Jul;50(7):2289-93. doi: 10.1016/j.fct.2012.03.077. Epub 2012 Apr 16.
106 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
107 Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther. 2009 Apr;329(1):252-61. doi: 10.1124/jpet.108.146225. Epub 2009 Jan 13.
108 Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
109 Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
110 Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36.
111 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
112 P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate. Toxicol Appl Pharmacol. 2016 Sep 1;306:27-35. doi: 10.1016/j.taap.2016.06.030. Epub 2016 Jul 1.
113 Potent Inhibitors of Organic Anion Transporters 1 and 3 From Natural Compounds and Their Protective Effect on Aristolochic Acid Nephropathy. Toxicol Sci. 2020 Jun 1;175(2):279-291. doi: 10.1093/toxsci/kfaa033.
114 Lack of efflux of diglycolic acid from proximal tubule cells leads to its accumulation and to toxicity of diethylene glycol. Toxicol Lett. 2023 Apr 15;379:48-55. doi: 10.1016/j.toxlet.2023.03.007. Epub 2023 Mar 22.
115 Inhibition of organic anion transporter (OAT) activity by cigarette smoke condensate. Toxicol In Vitro. 2017 Oct;44:27-35.
116 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
117 Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
118 Rifampin Regulation of Drug Transporters Gene Expression and the Association of MicroRNAs in Human Hepatocytes. Front Pharmacol. 2016 Apr 26;7:111.
119 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
120 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
121 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
122 Vitamin D3 transactivates the zinc and manganese transporter SLC30A10 via the Vitamin D receptor. J Steroid Biochem Mol Biol. 2016 Oct;163:77-87.
123 Neonicotinoid pesticides poorly interact with human drug transporters. J Biochem Mol Toxicol. 2019 Oct;33(10):e22379. doi: 10.1002/jbt.22379. Epub 2019 Jul 31.
124 Multiple drug transporters mediate the placental transport of sulpiride. Arch Toxicol. 2017 Dec;91(12):3873-3884. doi: 10.1007/s00204-017-2008-8. Epub 2017 Jun 9.
125 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
126 Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
127 Acetaminophen selectively suppresses peripheral prostaglandin E2 release and increases COX-2 gene expression in a clinical model of acute inflammation. Pain. 2007 Jun;129(3):279-86.
128 Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
129 Mitochondrial involvement in schizophrenia and other functional psychoses. Neurochem Res. 1996 Sep;21(9):995-1004.
130 Quercetin reduces oxidative damage induced by paraquat via modulating expression of antioxidant genes in A549 cells. J Appl Toxicol. 2013 Dec;33(12):1460-7. doi: 10.1002/jat.2812. Epub 2012 Sep 20.
131 Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
132 D-Penicillamine targets metastatic melanoma cells with induction of the unfolded protein response (UPR) and Noxa (PMAIP1)-dependent mitochondrial apoptosis. Apoptosis. 2012 Oct;17(10):1079-94.
133 Retinoic acid and its 4-oxo metabolites are functionally active in human skin cells in vitro. J Invest Dermatol. 2005 Jul;125(1):143-53.
134 The differential effects of bupivacaine and lidocaine on prostaglandin E2 release, cyclooxygenase gene expression and pain in a clinical pain model. Anesth Analg. 2008 Jan;106(1):321-7, table of contents.
135 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
136 Docosahexaenoic acid regulates gene expression in HUVEC cells treated with polycyclic aromatic hydrocarbons. Toxicol Lett. 2015 Jul 16;236(2):75-81.
137 Etoposide induces necrosis through p53-mediated antiapoptosis in human kidney proximal tubule cells. Toxicol Sci. 2015 Nov;148(1):204-19.
138 Conjugated linoleic acid, unlike other unsaturated fatty acids, strongly induces glutathione synthesis without any lipoperoxidation. Br J Nutr. 2006 Nov;96(5):811-9.
139 COX-2 and PPAR-gama confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther. 2013 Jan;12(1):69-82.
140 Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007 Dec;17(12):774-80.
141 Stimulation of cyclooxygenase-2 expression by bone-derived transforming growth factor-beta enhances bone metastases in breast cancer. Cancer Res. 2006 Feb 15;66(4):2067-73.
142 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
143 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
144 A2E selectively induces cox-2 in ARPE-19 and human neural cells. Curr Eye Res. 2006 Mar;31(3):259-63.
145 Cannabidiol enhances cytotoxicity of anti-cancer drugs in human head and neck squamous cell carcinoma. Sci Rep. 2020 Nov 26;10(1):20622. doi: 10.1038/s41598-020-77674-y.
146 Harnessing autophagy to overcome mitogen-activated protein kinase kinase inhibitor-induced resistance in metastatic melanoma. Br J Dermatol. 2019 Feb;180(2):346-356. doi: 10.1111/bjd.17333. Epub 2018 Nov 25.
147 TAp73 knockout mice show morphological and functional nervous system defects associated with loss of p75 neurotrophin receptor. Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):18952-7. doi: 10.1073/pnas.1221172110. Epub 2013 Nov 4.
148 A comparison of the effectiveness of selected non-steroidal anti-inflammatory drugs and their derivatives against cancer cells in vitro. Cancer Chemother Pharmacol. 2008 Feb;61(2):203-14. doi: 10.1007/s00280-007-0462-3. Epub 2007 Apr 20.
149 Identification of vitamin D3 target genes in human breast cancer tissue. J Steroid Biochem Mol Biol. 2016 Nov;164:90-97.
150 The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62.
151 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
152 Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
153 Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. Chem Biol Interact. 2011 May 30;191(1-3):227-33.
154 In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 Feb;18(2):109-20.
155 AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem Biol Interact. 2009 Mar 16;178(1-3):138-44.
156 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
157 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
158 A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan Ocul Toxicol. 2010 Sep;29(3):171-92.
159 Aberrantly expressed genes in HaCaT keratinocytes chronically exposed to arsenic trioxide. Biomark Insights. 2011 Feb 8;6:7-16.
160 Thyroid hormone responsive genes in cultured human fibroblasts. J Clin Endocrinol Metab. 2005 Feb;90(2):936-43.
161 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
162 Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line. Chem Biol Interact. 2013 Feb 25;202(1-3):218-25.
163 Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
164 Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
165 Initro inhibition of AKR1Cs by sulphonylureas and the structural basis. Chem Biol Interact. 2015 Oct 5;240:310-5.
166 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
167 Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 2018 Jun;92(6):1939-1952.
168 Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
169 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
170 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
171 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
172 Effects of histamine H2-receptor blockade on the cardiovascular reflex response to lower-body negative pressure in man. Acta Physiol Scand. 1990 May;139(1):161-72. doi: 10.1111/j.1748-1716.1990.tb08909.x.
173 Addition of acebutolol to diuretics in hypertension. Clin Pharmacol Ther. 1981 Dec;30(6):739-44. doi: 10.1038/clpt.1981.232.
174 Relative potency of a beta-blocking and a calcium entry blocking agent as antihypertensive drugs in black patients. Eur J Clin Pharmacol. 1986;29(5):523-7. doi: 10.1007/BF00635887.
175 Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. Hypertension. 2006 Jul;48(1):120-6. doi: 10.1161/01.HYP.0000225424.13138.5d. Epub 2006 May 22.
176 Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis. Am J Med. 1990 Sep;89(3):313-21. doi: 10.1016/0002-9343(90)90344-d.
177 Effects of an angiotensin converting enzyme inhibitor, ramipril, on intracranial circulation in healthy volunteers. off. Br J Clin Pharmacol. 1992 Sep;34(3):224-30. doi: 10.1111/j.1365-2125.1992.tb04128.x.
178 Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. Am J Physiol Renal Physiol. 2005 May;288(5):F1044-52. doi: 10.1152/ajprenal.00142.2004. Epub 2004 Dec 21.
179 beta-Endorphin and essential hypertension: importance of the clonidine-naloxone interaction. Acta Physiol Hung. 1985;65(2):217-26.
180 Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med. 1983 Dec 8;309(23):1414-9. doi: 10.1056/NEJM198312083092303.
181 Detection of low-renin hypertension; evaluation of out-patient renin-stimulating methods. Clin Sci Mol Med. 1975 Feb;48(2):91-6. doi: 10.1042/cs0480091.
182 Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
183 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
184 A protein-coated magnetic beads as a tool for the rapid drug-protein binding study. J Pharm Biomed Anal. 2010 Jul 8;52(3):420-4. doi: 10.1016/j.jpba.2009.06.023. Epub 2009 Jun 18.
185 The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties. J Biol Chem. 1999 Oct 8;274(41):29303-10. doi: 10.1074/jbc.274.41.29303.
186 Exploring binding properties of sertraline with human serum albumin: Combination of spectroscopic and molecular modeling studies. Chem Biol Interact. 2015 Dec 5;242:235-46. doi: 10.1016/j.cbi.2015.10.006. Epub 2015 Oct 22.
187 Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
188 Use of peak decay analysis and affinity microcolumns containing silica monoliths for rapid determination of drug-protein dissociation rates. J Chromatogr A. 2011 Apr 15;1218(15):2072-8. doi: 10.1016/j.chroma.2010.09.070. Epub 2010 Oct 16.
189 [Colchicine in chronic liver disease of alcoholic etiology. Double-blind, randomized study of its effects on blood levels of plasma proteins and clinical course in patients]. Rev Assoc Med Bras (1992). 1995 May-Jun;41(3):207-12.
190 Editor's Highlight: Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver Tissues. Toxicol Sci. 2016 Dec;154(2):354-367. doi: 10.1093/toxsci/kfw169. Epub 2016 Sep 7.
191 Covalent binding of the flavonoid quercetin to human serum albumin. J Agric Food Chem. 2005 May 18;53(10):4194-7. doi: 10.1021/jf050061m.
192 Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
193 Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
194 Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
195 Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
196 Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
197 Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
198 Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
199 Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
200 Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.
201 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
202 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
203 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
204 Chromosomal radiosensitivity in two cell lineages derived from clinically radiosensitive cancer patients. Clin Cancer Res. 2005 Sep 1;11(17):6352-8. doi: 10.1158/1078-0432.CCR-04-1931.
205 The proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide. Exp Hematol. 2011 Jan;39(1):55-65.
206 Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
207 Neuroprotective effects of glucomoringin-isothiocyanate against H(2)O(2)-Induced cytotoxicity in neuroblastoma (SH-SY5Y) cells. Neurotoxicology. 2019 Dec;75:89-104. doi: 10.1016/j.neuro.2019.09.008. Epub 2019 Sep 12.
208 Blood cell oxidative stress precedes hemolysis in whole blood-liver slice co-cultures of rat, dog, and human tissues. Toxicol Appl Pharmacol. 2010 May 1;244(3):354-65. doi: 10.1016/j.taap.2010.01.017. Epub 2010 Feb 6.
209 Molecular mechanisms of hepatotoxic cholestasis by clavulanic acid: Role of NRF2 and FXR pathways. Food Chem Toxicol. 2021 Dec;158:112664. doi: 10.1016/j.fct.2021.112664. Epub 2021 Nov 9.
210 Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun. 2002 Feb 8;290(5):1427-33. doi: 10.1006/bbrc.2002.6367.
211 Flavonoids increase the intracellular glutathione level by transactivation of the gamma-glutamylcysteine synthetase catalytical subunit promoter. Free Radic Biol Med. 2002 Mar 1;32(5):386-93. doi: 10.1016/s0891-5849(01)00812-7.
212 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
213 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
214 Glycidamide and cis-2-butene-1,4-dial (BDA) as potential carcinogens and promoters of liver cancer - An in vitro study. Food Chem Toxicol. 2022 Aug;166:113251. doi: 10.1016/j.fct.2022.113251. Epub 2022 Jun 21.
215 Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Mol Cancer Ther. 2009 May;8(5):1197-206.
216 Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
217 Essential role of Nrf2 in keratinocyte protection from UVA by quercetin. Biochem Biophys Res Commun. 2009 Sep 11;387(1):109-14. doi: 10.1016/j.bbrc.2009.06.136. Epub 2009 Jul 1.
218 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.
219 Motexafin gadolinium and zinc induce oxidative stress responses and apoptosis in B-cell lymphoma lines. Cancer Res. 2005 Dec 15;65(24):11676-88.
220 Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
221 Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005 Mar;128(5):636-44.
222 An in vitro skin sensitization assay termed EpiSensA for broad sets of chemicals including lipophilic chemicals and pre/pro-haptens. Toxicol In Vitro. 2017 Apr;40:11-25. doi: 10.1016/j.tiv.2016.12.005. Epub 2016 Dec 10.
223 Regulation of CYP4A expression by bezafibrate in primary culture of rat and human hepatocytes: interspecies difference and influence of N-acetylcysteine. Toxicol In Vitro. 2009 Oct;23(7):1259-67.
224 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
225 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
226 Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of Captopril in women. Clin Pharmacol Ther. 2007 Aug;82(2):187-96. doi: 10.1038/sj.clpt.6100214. Epub 2007 May 2.
227 Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res. 2012 Aug;349(2):551-63. doi: 10.1007/s00441-012-1417-5. Epub 2012 May 13.
228 Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
229 ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010 May;87(5):558-62.
230 Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
231 Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
232 Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
233 Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.